| Entry |
|
|---|
| Name |
Enfortumab vedotin (USAN);
Enfortumab vedotin (genetical recombination) (JAN);
Enfortumab vedotin-ejfv;
Padcev (TN) |
|---|
| Product |
|
|---|
| Formula |
C6642H10284N1742O2063S46
|
|---|
| Exact mass |
148930.0517
|
|---|
| Mol weight |
149022.148
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, Nectin-4 antibody, Tubulin polymerization inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Antibody-drug conjugate
Treatment of cancers expressing Nectin-4
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC36 Enfortumab vedotin
D11525 Enfortumab vedotin (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Enfortumab Vedotin
D11525 Enfortumab vedotin (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11525 Enfortumab vedotin (USAN); Enfortumab vedotin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
Other
PVRL4 (NECTIN4)
D11525 Enfortumab vedotin (USAN) <JP/US>
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D11525 Enfortumab vedotin (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11525
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11525
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11525
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
